Membrane-anchored and tumor-targeted IL-12-armed (attIL12) T cells therapy(The University of Texas MD Anderson Cancer Center)

N/A

Report date: 2024/07/02 17:47:43

Base Information

Drug NameMembrane-anchored and tumor-targeted IL-12-armed (attIL12) T cells therapy(The University of Texas MD Anderson Cancer Center)
Drug Alias NameattIL12
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionInterleukin-12 modulatorsT lymphocyte replacements
TargetsInterleukin-12
Therapy Area/IndicationsOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A